STOCK TITAN

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Purple Biotech (NASDAQ/TASE: PPBT) has been selected to present data on its CAPTN-3 platform at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, from October 23-25, 2024. The poster, titled "CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers," will be presented by Dr. Hadas Reuveni, VP R&D of Purple Biotech.

CAPTN-3 is a first-in-class platform of conditionally activated tri-specific antibodies that engage both T cells and NK cells with tumors, creating an enhanced immune response against cancer. The company's lead candidate, IM1240, targets 5T4, a tumor-associated antigen overexpressed in various solid tumors and linked to poor clinical outcomes. 5T4's specific expression pattern in cancer cells makes it an ideal target for therapeutic approaches in lung, gastric, head and neck, and other cancers.

Purple Biotech (NASDAQ/TASE: PPBT) è stata selezionata per presentare dati sulla sua piattaforma CAPTN-3 al 36° Simposio EORTC-NCI-AACR sui Target Molecolari e le Terapie Antitumorali che si terrà a Barcellona, Spagna, dal 23 al 25 ottobre 2024. Il poster, intitolato "CAPTN-3: Una nuova piattaforma di attivatori di cellule T e cellule NK condizionatamente attivati," sarà presentato dalla Dr.ssa Hadas Reuveni, VP R&D di Purple Biotech.

CAPTN-3 è una piattaforma di anticorpi tri-specifici condizionatamente attivati di prima classe che attiva sia le cellule T che le cellule NK contro i tumori, creando una risposta immunitaria potenziata contro il cancro. Il candidato principale dell'azienda, IM1240, è mirato al 5T4, un antigene associato al tumore sovraespresso in vari tumori solidi e collegato a scarsi risultati clinici. Il pattern di espressione specifico del 5T4 nelle cellule tumorali lo rende un target ideale per approcci terapeutici nei tumori polmonari, gastrici, testa e collo, e in altri tipi di cancro.

Purple Biotech (NASDAQ/TASE: PPBT) ha sido seleccionada para presentar datos sobre su plataforma CAPTN-3 en el 36º Simposio EORTC-NCI-AACR sobre Objetivos Moleculares y Terapias contra el Cáncer que se llevará a cabo en Barcelona, España, del 23 al 25 de octubre de 2024. El póster, titulado "CAPTN-3: Una nueva plataforma de activadores de células T y células NK activados condicionalmente," será presentado por la Dra. Hadas Reuveni, VP de I+D de Purple Biotech.

CAPTN-3 es una plataforma de anticuerpos tri-específicos de primera clase activados condicionalmente que involucra tanto a células T como a células NK en tumores, creando una respuesta inmunitaria mejorada contra el cáncer. El candidato principal de la empresa, IM1240, se dirige al 5T4, un antígeno asociado a tumores sobreexpresado en varios tumores sólidos y relacionado con malos resultados clínicos. El patrón de expresión específico del 5T4 en las células cancerosas lo convierte en un objetivo ideal para enfoques terapéuticos en cánceres de pulmón, gástrico, de cabeza y cuello, y otros tipos de cáncer.

Purple Biotech (NASDAQ/TASE: PPBT)는 2024년 10월 23일부터 25일까지 스페인 바르셀로나에서 열리는 제36회 EORTC-NCI-AACR 분자 표적 및 암 치료 심포지엄에서 CAPTN-3 플랫폼에 대한 데이터를 발표하기 위해 선정되었습니다. "CAPTN-3: 조건부 활성화 T 세포 및 NK 세포 활성화기의 새로운 플랫폼"이라는 제목의 포스터는 Purple Biotech의 연구 개발 부사장인 Hadas Reuveni 박사에 의해 발표됩니다.

CAPTN-3는 T 세포와 NK 세포를 종양에 결합시키는 조건부 활성화 삼중 특정 항체의 1세대 플랫폼으로, 암에 대한 강화된 면역 반응을 생성합니다. 회사의 주요 후보인 IM1240은 다양한 고형 종양에서 과발현되며 불량한 임상 결과와 연결된 종양 관련 항원인 5T4를 타겟으로 합니다. 5T4의 암세포 내 특정 발현 패턴은 폐암, 위암, 두경부 및 기타 암에 대한 치료적 접근 방식의 이상적인 타겟이 됩니다.

Purple Biotech (NASDAQ/TASE: PPBT) a été sélectionnée pour présenter des données sur sa plateforme CAPTN-3 lors du 36e Symposium EORTC-NCI-AACR sur les cibles moléculaires et les thérapies du cancer, qui se tiendra à Barcelone, Espagne, du 23 au 25 octobre 2024. L'affiche, intitulée "CAPTN-3 : Une plateformenovel d'engagements de cellules T et de cellules NK activées conditionnellement," sera présentée par Dr. Hadas Reuveni, VP R&D de Purple Biotech.

CAPTN-3 est une plateforme de premiers de catégorie d'anticorps tri-spécifiques activés conditionnellement qui engagent à la fois les cellules T et les cellules NK avec des tumeurs, créant une réponse immunitaire renforcée contre le cancer. Le candidat principal de l'entreprise, IM1240, cible le 5T4, un antigène associé aux tumeurs surexprimé dans divers cancers solides et lié à de mauvais résultats cliniques. Le motif d’expression spécifique du 5T4 dans les cellules cancéreuses en fait une cible idéale pour des approches thérapeutiques dans les cancers du poumon, gastriques, de la tête et du cou, ainsi que d'autres cancers.

Purple Biotech (NASDAQ/TASE: PPBT) wurde ausgewählt, um Daten zu ihrer CAPTN-3-Plattform auf dem 36. EORTC-NCI-AACR-Symposium zu molekularen Zielen und Krebsbehandlungen, das vom 23. bis 25. Oktober 2024 in Barcelona, Spanien, stattfindet, zu präsentieren. Das Poster mit dem Titel "CAPTN-3: Eine neuartige Plattform für bedingt aktivierte T-Zellen und NK-Zellen" wird von Dr. Hadas Reuveni, VP für Forschung und Entwicklung bei Purple Biotech, vorgestellt.

CAPTN-3 ist eine erstklassige Plattform für bedingt aktivierte tri-spezifische Antikörper, die sowohl T-Zellen als auch NK-Zellen mit Tumoren aktivieren und eine verstärkte Immunantwort gegen Krebs erzeugen. Der Hauptkandidat des Unternehmens, IM1240, zielt auf 5T4 ab, ein tumorassoziiertes Antigen, das in verschiedenen soliden Tumoren überexprimiert wird und mit schlechten klinischen Ergebnissen verbunden ist. Das spezifische Expressionsmuster von 5T4 in Krebszellen macht es zu einem idealen Ziel für therapeutische Ansätze bei Lungen-, Magen-, Kopf- und Halskrebs sowie bei anderen Krebsarten.

Positive
  • None.
Negative
  • None.

CAPTN-3 is a conditionally activated tri-specific antibody platform that features novel dual engagement of T cells and NK cells to mount an optimal anti-tumoral immune response against cancer

REHOVOT, Israel, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced it has been selected for a poster presentation at the 36th European Organization for Research and Treatment of Cancer, National Cancer Institute,  American Association for Cancer Research (EORTC-NCI-AACR) Symposium on Molecular Targets and Cancer Therapeutics (the “Triple Meeting”) held October 23-25, 2024 in Barcelona, Spain.

Purple Biotech’s poster titled “CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers” (Abstract # 450, poster board number: PB438) will be presented by Dr. Hadas Reuveni, VP R&D of Purple Biotech, during a ‘New therapies in immuno oncology’ poster session on Friday, 25 October 2024.     

CAPTN-3 is a First-in-class platform of conditionally activated tri-specific antibodies engaging both T cells and NK cells with the tumor to create an immune synapse with enhanced anti-tumor efficacy. The NK engager arm (aNKG2A) of our lead compound also acts as a checkpoint inhibitor for both NK cells and highly cytotoxic T cell subsets, unleashing both innate and adaptive immune subsets against the tumor.

Purple Biotech’s lead CAPTN-3 platform candidate, IM1240, targets 5T4 as a tumor associated antigen (TAA), which is overexpressed in a variety of solid tumors and is correlated with advanced disease, increased invasiveness, and poor clinical outcome. 5T4, also known as trophoblast glycoprotein (TPBG), is an oncofetal surface protein that is not found on adult healthy tissues but is abnormally expressed in several cancer types. This specific expression pattern as well as the correlation with poor prognosis in different cancer diseases such as lung, gastric, head and neck and other cancers makes it an ideal TAA for various therapeutic approaches.

About Purple Biotech

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company's oncology pipeline includes CM24, NT219 and IM1240. CM24 is a humanized monoclonal antibody that blocks CEACAM1, that supports tumor immune evasion and survival through multiple pathways. CEACAM1 on tumor cells, immune cells and neutrophils extracellular traps is a novel target for the treatment of multiple cancer indications. As a proof of concept of these novel pathways, the Company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma (PDAC). The Company has entered into a clinical collaboration agreement with Bristol Myers Squibb for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. A Phase 1 dose escalation study was concluded as a monotherapy and in combination with cetuximab in which NT219 demonstrated anti-tumor activity in combination with cetuximab in second line patients with recurrent and/or metastatic SCCHN (R/N SCCHN). The Company is advancing CAPTN-3, a preclinical platform of conditionally-activated tri-specific antibody that engages both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The cleavable capping technology confines the compound's therapeutic activity to the local tumor microenvironment, and thereby potentially increases the anticipated therapeutic window in patients. The third arm specifically targets the Tumor Associated Antigen (TAA).  The technology presents a novel mechanism of action by unleashing both innate and adaptive immune systems to mount an optimal anti-tumoral immune response. IM1240 is the first tri-specific antibody in development that targets 5T4 expressed in a variety of solid tumors and is correlated with advanced disease, increased invasiveness and poor clinical outcomes. The Company's corporate headquarters are located in Rehovot, Israel. For more information, please visit https://purple-biotech.com/.

Forward-Looking Statements and Safe Harbor Statement

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for NT219, CM24 and IM1240; the process by which such early stage therapeutic candidates could potentially lead to an approved drug product is long and subject to highly significant risks, particularly with respect to a joint development collaboration; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents; the commencement of any patent interference or infringement action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2023 and in our other filings with the U.S. Securities and Exchange Commission ("SEC"), including our cautionary discussion of risks and uncertainties under "Risk Factors" in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC's website, https://www.sec.gov.

CONTACTS:

Company Contact:
Lior Fhima
Chief Financial Officer
IR@purple-biotech.com


FAQ

What is Purple Biotech's CAPTN-3 platform and when will it be presented?

CAPTN-3 is Purple Biotech's conditionally activated tri-specific antibody platform that engages both T cells and NK cells to fight cancer. It will be presented at the EORTC-NCI-AACR Symposium on October 25, 2024, in Barcelona, Spain.

What is the target of Purple Biotech's lead CAPTN-3 candidate IM1240?

Purple Biotech's lead CAPTN-3 candidate IM1240 targets 5T4, also known as trophoblast glycoprotein (TPBG), which is a tumor-associated antigen overexpressed in various solid tumors and linked to poor clinical outcomes.

How does the CAPTN-3 platform work to fight cancer?

CAPTN-3 creates an immune synapse with enhanced anti-tumor efficacy by engaging both T cells and NK cells with the tumor. It also includes an NK engager arm that acts as a checkpoint inhibitor for NK cells and cytotoxic T cell subsets, unleashing both innate and adaptive immune responses against the tumor.

What types of cancers could potentially be treated with Purple Biotech's CAPTN-3 technology?

The CAPTN-3 technology, particularly the IM1240 candidate targeting 5T4, could potentially treat various solid tumors including lung, gastric, head and neck, and other cancers where 5T4 is overexpressed and associated with poor prognosis.

Purple Biotech Ltd. American Depositary Shares

NASDAQ:PPBT

PPBT Rankings

PPBT Latest News

PPBT Stock Data

4.01M
1.51M
2.87%
9.33%
1.25%
Biotechnology
Healthcare
Link
United States of America
Rehovot